Contact Us

    Contact Us

    Axtria Inc. 300
    Connell Drive, 5th & 6th Floor,
    Berkeley Heights, NJ 07922
    United States

    +1-877-929-8742
    connect@axtria.com


    Copyright © 2023 Axtria. All Rights Reserved.

    Axtria Cookie Policy & Privacy Statement.

    Contact Us

    Meet our leaders at ISPOR Europe 2022

    Won Chen Lee

    Won Chan Lee, Ph.D.
    Principal and Head, RWE/HEOR, Axtria

    Dr. Lee has more than 17 years of experience in health economics and outcomes research (HEOR) including strategic planning, economic modelling, RWE database studies, post-marketing studies, HRQL/PRO assessments, HEOR roadmap, value proposition development, HTA assessment, publication strategies, etc. He serves as RWE/HEOR practice lead and principal at Axtria. Dr. Lee holds a PhD in Health Economics from the Graduate Centre of the City University, New York and a master’s degree in Economics from the University of Grenoble, France.

    Jennifer Ken Opurum

    Jennifer Ken-Opurum, Ph.D.
    Associate Director, RWE/HEOR, Axtria

    Dr. Ken Opurum is an experienced consultant and RWE researcher providing solutions to key business problems for clients in the pharma and biotech domain. Dr. Ken-Opurum has been responsible for providing strategic insights and leading teams of research analysts and data scientists on secondary database analysis, primary patient / stakeholder surveys, patient chart revies, prospective cohort studies, etc. Dr. Ken-Opurum holds a PhD in Nutrition Science and Bachelor of Science in Dietetics from Purdue University, USA.

    In-person poster session

    Monday, November 7, 2022
    15:00 to 18:15 (CET)

    Clinical and economic outcomes associated with use of anti-arrhythmic drugs versus ablation in Atrial Fibrillation (AFib)

    Ken-Opurum J, Vadagam P, Srinivas SSS, Faith L, Preblick R, Park S, Charland S, Revel A

    The objective of this study was to evaluate the economic benefits of anti-arrhythmic drugs (AADs) in comparison with ablation from a US payer perspective. A Rhythm Control Economic model was used to compare different treatment scenarios assess the economic benefits of AADs (dronedarone, amiodarone, sotalol, flecainide, propafenone, dofetilide, and AADs as a group) vs ablation. The results of the study bring forward interesting insights in comparison of direct and combination therapies.

     

    Tuesday, November 8, 2022
    15:00 to 18:15 (CET)

    The economic value of Insulin glargine 300 U/Ml (GLA-300) in people ≥18 years of age with type 2 diabetes mellitus: A value-based economic model from a U.S. payer perspective

    Ponomareva E, Siegfried C, Srinivas SSS, Preblick R, Park S, Wilson L, Revel A

    This study incorporates real-world evidence (RWE) in a value-based budget impact model (BIM) to demonstrate the value and affordability of Gla-300 for the treatment of adult patients with type 2 diabetes mellitus (T2DM) receiving basal insulins (Bis) from a U.S. payer perspective. A prevalence-based modelling approach was employed, consisting of three types of patients receiving BIs: prevalent patients (have been on insulin treatment for at least one year), naïve patients (new to the BI treatment, less than one year), switchers (previously naïve or prevalent patients who have switched insulin treatments). The model assessed the cost of treatment (drug costs), hypoglycemic events (associated with emergency, inpatient, and outpatient visits), and diabetes-related healthcare resource utilization (HCRU) costs (associated with emergency, inpatient, and outpatient visits). The study presented base case results by patient population, type in different scenarios.

    Discuss your business needs and challenges with us.

    Want to know more about Axtria’s offerings in RWE/HEOR?

    Please contact Won Chan Lee and Chet Baboor at connect@axtria.com.

    Learn more about our work and thought leadership

    HEOR Value Demonstration And Evidence Generation Challenges
    Seeing The Whole Elephant: Integrated Advanced Data Analytics In Support Of RWE
    The Relationship Between Drug Price Controls And Patient Health Outcomes